Russia has approved a second COVID-19 vaccine, the EpiVacCorona vaccine developed at the Vector Institute in Siberia.

The approval was granted ahead of a planned 30,000-participant phase 3 trial.

In August, Russian approved Sputnik V, the world’s first COVID-19 vaccine, prompting international concern because it had not gone through a late-stage study. Sputnik V is currently undergoing phase 3 trials in Russia, Saudi Arabia, Belarus and the Philippines.